Imipramine oxide

Jump to: navigation, search
Imipramine oxide
Imipramine wiki str.png
Clinical data
Routes of
administration
oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H24N2O
Molar mass296.41 g/mol

WikiDoc Resources for Imipramine oxide

Articles

Most recent articles on Imipramine oxide

Most cited articles on Imipramine oxide

Review articles on Imipramine oxide

Articles on Imipramine oxide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Imipramine oxide

Images of Imipramine oxide

Photos of Imipramine oxide

Podcasts & MP3s on Imipramine oxide

Videos on Imipramine oxide

Evidence Based Medicine

Cochrane Collaboration on Imipramine oxide

Bandolier on Imipramine oxide

TRIP on Imipramine oxide

Clinical Trials

Ongoing Trials on Imipramine oxide at Clinical Trials.gov

Trial results on Imipramine oxide

Clinical Trials on Imipramine oxide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Imipramine oxide

NICE Guidance on Imipramine oxide

NHS PRODIGY Guidance

FDA on Imipramine oxide

CDC on Imipramine oxide

Books

Books on Imipramine oxide

News

Imipramine oxide in the news

Be alerted to news on Imipramine oxide

News trends on Imipramine oxide

Commentary

Blogs on Imipramine oxide

Definitions

Definitions of Imipramine oxide

Patient Resources / Community

Patient resources on Imipramine oxide

Discussion groups on Imipramine oxide

Patient Handouts on Imipramine oxide

Directions to Hospitals Treating Imipramine oxide

Risk calculators and risk factors for Imipramine oxide

Healthcare Provider Resources

Symptoms of Imipramine oxide

Causes & Risk Factors for Imipramine oxide

Diagnostic studies for Imipramine oxide

Treatment of Imipramine oxide

Continuing Medical Education (CME)

CME Programs on Imipramine oxide

International

Imipramine oxide en Espanol

Imipramine oxide en Francais

Business

Imipramine oxide in the Marketplace

Patents on Imipramine oxide

Experimental / Informatics

List of terms related to Imipramine oxide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Imipraminoxide (Imiprex, Elepsin), or imipramine N-oxide, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.[1][2][3][4]

Imipraminoxide is both an analogue and a metabolite of imipramine, and has similar effects.[5][6][7][8] However, in clinical trials, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked side effects, including diminished orthostatic hypotension and anticholinergic effects like dry mouth, sweating, dizziness, and fatigue.[5][6][7][8][9][10]

Imipraminoxide's pharmacology has not been well elucidated, but based on its very close relationship with imipramine, it likely acts as a serotonin and norepinephrine reuptake inhibitor and serotonin, adrenenaline, histamine, and muscarinic acetylcholine receptor antagonist, though with weaker antiadrenergic and anticholinergic actions.[9][10]

See also

References

  1. Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 546. ISBN 3-88763-075-0.
  2. Dictionary of organic compounds. London: Chapman & Hall. 1996. p. 3877. ISBN 0-412-54090-8.
  3. FAURBYE A, JACOBSEN O, KRISTJANSEN P, MUNKVAD I (September 1963). "Imipramine-N-oxide: preliminary investigation of a new antidepressive drug". The American Journal of Psychiatry. 120: 277–8. PMID 13944543.
  4. Lingjaerde O (November 1971). "[Imiprex "Dumex" (imipramine oxide). A new tricyclic antidepressive agent]". Tidsskrift for Den Norske Lægeforening : Tidsskrift for Praktisk Medicin, Ny Række (in Norwegian). 91 (31): 2267–8. PMID 5133241.
  5. 5.0 5.1 Rapp W, Norén MB, Pedersen F (1973). "Comparative trial of imipramine N-oxide and imipramine in the treatment of out-patients with depressive syndromes". Acta Psychiatrica Scandinavica. 49 (1): 77–90. doi:10.1111/j.1600-0447.1973.tb04400.x. PMID 4572170.
  6. 6.0 6.1 Aronson, Jeffrey Kenneth (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. p. 34. ISBN 0-444-53266-8.
  7. 7.0 7.1 Dencker SJ (1971). "[Clinical trial with imipramine-N-oxide and amitriptyline-N-oxide]". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry (in Swedish). 25 (5): 463–70. PMID 4947298.
  8. 8.0 8.1 Beale, John Marlowe; Wilson, Charles Henry; Gisvold, Ole; Block, John H. (2004). Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 87. ISBN 0-7817-3481-9.
  9. 9.0 9.1 Dencker SJ, Bake B (July 1976). "Investigation of the orthostatic reaction after intravenous administration of imipramine, chlorimipramine, and inimpramine-N-oxide". Acta Psychiatrica Scandinavica. 54 (1): 74–8. doi:10.1111/j.1600-0447.1976.tb00095.x. PMID 952235.
  10. 10.0 10.1 Clemmesen L, Mikkelsen PL, Lund H, Bolwig TG, Rafaelsen OJ (1984). "Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels". Psychopharmacology. 82 (4): 348–54. doi:10.1007/BF00427684. PMID 6427827.

Template:Tricyclics


Template:Nervous-system-drug-stub


Linked-in.jpg